Professor Osagie Imasogie

Founder, Phoenix IP Ventures

Prior to co-founding Phoenix IP Ventures, an IP based Merchant Bank, Professor Imasogie conceptualized and established GlaxoSmithKline Ventures and was its founding Vice President. Previously, Osagie was a Vice President for Product Development Strategy at SmithKline Beecham, a DuPont Merck Vice President for International Sales and Marketing and General Counsel to DuPont Merck’s International, Manufacturing and Generic Drug Divisions, the Founding Senior Vice President for Business Development and General Counsel at Endo Pharmaceuticals Inc., a Price Waterhouse Corporate Finance Partner and the Partner-in-Charge for PW Corporate Finance and IT activities for West Africa, as well as a practicing attorney with a leading US Law Firm in the fields of corporate, corporate finance, taxation and intellectual property law.

Most recently, Osagie was a co-Founder and former President, CEO and Chairman of Ception Therapeutics, Inc. and also the Founder of Trigenesis Therapeutics Inc. Osagie is currently the Chairman of Iroko Pharmaceuticals and iCeutica, Inc. In addition, Osagie serves on the Board of several financial institutions such as Quoin Capital and StoneRidge Investment Partners and charitable organizations such as The Philadelphia Museum of Art and The Philadelphia Orchestra and educational institutions such as the University of Pennsylvania and the University of Pennsylvania Law School. Osagie also served as a Senior Consultant to the President’s Emergency Plan For Aids Relief (PEPFAR), a unique initiative by the United States Government to have a direct, positive impact in the fight against the global Aids epidemic by committing $48 billion and a multifaceted approach to combating HIV/AIDS. Osagie holds post-graduate degrees from the London School of Economics and the University of Pennsylvania Law School, and is a member of the New York State Bar. In addition, Osagie is an Adjunct Professor at the University of Pennsylvania Law School where he teaches a seminar on “Intellectual Property and National Economic Value Creation”.